Table 4.
Percentage of control (non-vaccinated) and Strain F Mycoplasma gallisepticum (FMG) in ovo-vaccinated1 Hy-Line W-36 layer chickens that tested positive2 for IgM and IgG antibody production against MG (Mycoplasma gallisepticum) from 0 to 28 d of age.
| IgM antibody production (% Serum plate agglutination positive) |
||||||||
|---|---|---|---|---|---|---|---|---|
| Hatch | D 2 | D 3 | D 5 | D 7 | D 14 | D 21 | D 28 | |
| Control | 0 | 0 | 0 | 0 | 0 | 0 | 1.9 | 0 |
| FMG in ovo | 0 | 0 | 0 | 0 | 1.9 | 31.5 | 55.9 | 60.6 |
| IgG antibody production (% ELISA positive) |
||||||||
| Control | NA | NA | NA | NA | NA | 0 | 0 | 0 |
| FMG in ovo | NA | NA | NA | NA | NA | 0 | 2.9 | 21.2 |
| Numbers of birds tested |
||||||||
| Control | 54 | 54 | 54 | 54 | 54 | 54 | 54 | 53 |
| FMG in ovo | 54 | 54 | 54 | 54 | 54 | 54 | 34 | 33 |
1
Chickens were vaccinated with Poulvac Myco F (Zoetis) live attenuated strain F Mycoplasma gallisepticum (FMG) vaccine at 18 d of incubation with a 10−6 dilution of the vaccine in a 50 µL volume. The vaccine was resuspended and diluted in Poulvac Marek's diluent (Zoetis, Exton, PA).
2
Blood samples collected from the birds were tested for IgM antibodies against MG by serum plate agglutination (SPA) testing and were tested for IgG antibodies against MG by ELISA testing.